OncBioMune Gets Approval for Andfrt in Mexico

Pharmaceutical Investing

OncBioMune Pharmaceuticals announced the registration of Andfrt, a male fertility product, was approved by the Mexican Ministry of Health.

OncBioMune Pharmaceuticals (OTCQB:OBMP) announced the registration of Andfrt, a male fertility product, was approved by the Mexican Ministry of Health.
As quoted in the press release:

OncBioMune has rights to Andfrt® for the Mexican market through an exclusive license agreement with QPharma, Inc. QPharma markets the product in Europe under the brand name Androferti®.
Andfrt®, a unique twice daily supplement, is a male fertility product containing an exclusive and balanced formula composed of L-Carnitine, antioxidants, vitamins and minerals. When taken for 3-6 months, clinical studies show that Andfrt® can improve sperm mobility, concentration and reduce sperm fragmentation.
Manufacturing of the first lot of Andfrt® is underway, with product launch expected late in the third quarter of 2017. OncBioMune’s marketing efforts will be focused on urologists and fertility clinics across the country. Based upon the success of Androferti in Europe, the Company anticipates revenue from Andfrt® of approximately US$150,000 from launch to the end of 2017 and over $500,000 in the first full year of sales.
“We are excited about another approval from Mexico’s Ministry of Health, which paves the way for our third product in the Mexican markets,” commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. “Sales of Bekunis® and Cirkused® are constantly growing and with the addition of Androferti, we’re on track for a solid 2017. Androferti is a popular fertility supplement in Europe and our research indicates that the product will be warmly received in Mexico as well. Next in queue is our Anti-D immunoglobulin product as we continue to build our footprint to become a household brand with a diverse portfolio of approved products in Mexico.

Click here to read the full press release.

Source: www.marketwired.com

The Conversation (0)